Celebrex (Celecoxib)

Evidence Anchor

BioHarmony 5.8/10

Celebrex (Celecoxib) is a 5.8 / 10 fit for people using anti inflammatory, acute pain, and chronic pain as a measured experiment, not a belief-based staple. The best anchors are [Derry S, Moore RA 2013](https://pubmed.ncbi.nlm.nih.gov/24150982/), which reports 10 studies and 1,785 participants and 400 mg celecoxib effective for acute postoperative pain, indirect comparison similar to ibuprofen 400 mg, and [Zeng X et al. 2026](https://pmc.ncbi.nlm.nih.gov/articles/PMC12813194/), which reports 11 randomized trials and 1,511 participants and imrecoxib and celecoxib had no significant overall difference in clinical response or pain VAS. That gives Celebrex (Celecoxib) a real signal, but the report should stay narrow because responder fit, baseline status, and outcome tracking drive the practical value. Use Celebrex (Celecoxib) when the target is specific, measurable, and worth the tradeoff. Skip or stop Celebrex (Celecoxib) when the expected symptom, lab, or performance marker stays flat. ✅ Best for: Adults with moderate-to-severe OA, RA symptoms, AS pain, acute postsurgical or dental pain, or primary dysmenorrhea when prescription NSAID therapy is justified. Celecoxib is most compelling when gastrointestinal risk makes nonselective NSAIDs less attractive and cardiovascular risk is low enough for a clinician to be comfortable. It can also be useful when pain relief enables physical therapy, walking, strength training, or sleep restoration. CYP2C9 normal metabolizers without established cardiovascular disease, recent heart attack or stroke, active ulcer disease, severe kidney or liver impairment, late pregnancy, or anticoagulant complexity fit the cleaner end of the risk profile. ❌ Avoid if: You are using celecoxib for longevity, workout recovery, cancer prevention, or general inflammation cleanup. Avoid celecoxib around CABG surgery, during late pregnancy unless specifically directed, with active or recent gastrointestinal bleeding, severe renal or hepatic impairment, prior serious NSAID skin reaction, known celecoxib hypersensitivity, recent heart attack or stroke, established cardiovascular disease unless a clinician decides otherwise, concurrent warfarin-like anticoagulation without close monitoring, or CYP2C9 poor-metabolizer status without dose adjustment. Also avoid it if you have not tried lower-risk foundations first: movement, weight management, physical therapy, sleep, and topical options where appropriate.

Read the full BioHarmony report

My score and my verdict: one signal of three, never the whole answer.